摘要
背景:主要目标是分析患者变量(抑郁,生活质量,抗痴呆药物治疗,痴呆相关知识)与正式诊断为痴呆的社区住院初级保健患者的筛查阳性痴呆。 方法:DelpHi-MV(痴呆:梅克伦堡 - 前波美拉尼亚的生活和以人为中心的帮助)是一项基于全科医生的随机对照干预试验。目前的分析是基于319名筛查阳性的筛查患者(70岁以上,居住在家中)在筛查之前未被正式诊断为痴呆的横断面数据。医疗诊断(ICD-10)是从患者的病历中检索出来的。在基线检查的筛查测试后,评估抑郁症(老年抑郁量表; GDS),阿尔茨海默病(QOL-AD)的生活质量,痴呆知识和抗痴呆药物治疗。 结果:在基线检查中,319例患者中有171例(54%)在筛查阳性后被正式诊断为痴呆。 (GDS≥6:11%vs. 15%; p = 0.396),生活质量(平均(SD):2.8(0.3)vs. 2.8(0.4)),单因素比较显示, ; p = 0.833)和痴呆相关知识(75%vs 75%; p> 0.999)。接受正规诊断的患者更常使用抗痴呆药物(20%比11%; p = 0.040)。控制混杂变量的多变量分析证实了这些发现。 结论:目前的研究结果并不支持在筛查后确定正式的痴呆诊断与潜在的危害有关的担忧。如果在前瞻性研究中得到证实,我们的数据表明患者可能从正式诊断为抗痴呆药物治疗中受益。
关键词: 痴呆症,筛查,初级保健,痴呆症的正式诊断,抑郁症,生活质量,抗痴呆药物治疗,DelpHi试验。
Current Alzheimer Research
Title:Patient Variables Associated with the Assignment of a Formal Dementia Diagnosis to Positively Screened Primary Care Patients
Volume: 15 Issue: 1
关键词: 痴呆症,筛查,初级保健,痴呆症的正式诊断,抑郁症,生活质量,抗痴呆药物治疗,DelpHi试验。
摘要: Background: Main objective was to analyze the associations of patient variables (depression, quality of life, anti-dementia drug treatment, knowledge about dementia) with the assignment of a formal diagnosis of dementia to community-dwelling primary care patients who have screened positive for dementia.
Methods: DelpHi-MV (Dementia: life- and person-centered help in Mecklenburg-Western Pomerania) is a general practitioner based randomized controlled intervention trial. Present analyses are based on cross-sectional data of 319 positively screened patients (age 70+, living at home) who had not been formally diagnosed with dementia before the screening. The medical diagnoses (ICD-10) were retrieved from the patient's medical records. Depression (Geriatric Depression Scale; GDS), quality of life in Alzheimer's disease (Qol-AD), knowledge about dementia, and anti-dementia drug treatment were assessed after the screening test at the baseline examination.
Results: At the baseline examination, 171 out of 319 patients (54%) had been formally diagnosed with dementia after they have screened positive. Univariate comparisons showed no statistically significant differences between diagnosed and undiagnosed patients regarding depression (GDS≥6: 11% vs. 15%; p=0.396), quality of life (mean (SD): 2.8 (0.3) vs. 2.8 (0.4); p=0.833), and the knowledge about dementia (75% vs. 75%; p>0.999). Patients who had received a formal diagnosis were more often treated with anti-dementia drugs (20% vs. 11%; p=0.040). Multivariate analyses controlled for confounding variables confirmed these findings.
Conclusion: Present findings do not support concerns that the assignment of a formal dementia diagnosis after screening is associated with potential harms. If confirmed in a prospective study, our data would suggest that patients may benefit from being formally diagnosed regarding anti-dementia drug treatment.
Export Options
About this article
Cite this article as:
Patient Variables Associated with the Assignment of a Formal Dementia Diagnosis to Positively Screened Primary Care Patients, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170908095707
DOI https://dx.doi.org/10.2174/1567205014666170908095707 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Familial Alzheimers Disease Mutations in Presenilin 1 Do Not Alter Levels of the Secreted Amyloid-β Protein Precursor Generated by β-Secretase Cleavage
Current Alzheimer Research Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetically-mediated Grey and White Matter Alteration in Normal Elderly Individuals with the CLU-C Allele Gene
Current Alzheimer Research Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy
Current Pharmaceutical Design Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease
Current Alzheimer Research Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
CNS & Neurological Disorders - Drug Targets Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research Is Alzheimers Disease a Myth? When is Disease a Disease?
Current Alzheimer Research Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry